Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Verve PCSK9-inhibitor gene therapy
Company

Verve PCSK9-inhibitor gene therapy

Tracked across 1 events · 11 articles · First seen Feb 11, 2026 · Last active Feb 11, 2026

Sentiment
70
Attention
6
Events
1
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 70
Tech
Gene-Editing for High Cholesterol Breakthrough
Verve PCSK9-inhibitor gene therapy, a subsidiary of Eli Lilly and Company, is pioneering a PCSK9-targeted gene-editing infusion that has demonstrated a similar reduction in LDL cholesterol in small studies. Its co-founder, Kiran Musunuru, notes the edits have lasted a lifetime in mice.
Feb 11, 2026 · 11 articles
Relationships (2)
CRISPR Therapeutics ↔ Verve PCSK9-inhibitor gene therapy Unknown
Kiran Musunuru co-founder ↔ Verve PCSK9-inhibitor gene therapy Kiran Musunuru is a co-founder of Verve PCSK9-inhibitor gene therapy.
NEWSDESK
Track Verve PCSK9-inhibitor gene therapy live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.